Fate Therapeutics Inc

FATE

$80.23

+165.2% (1 year change)

Avg closing price

Price range

Market Cap

$7.92 Billion

The market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.

52 Week Range

$29.37 - $121.16

The lowest and highst price in the last 52 weeks.

Price-Earnings Ratio

0.0x

The price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.

Dividends per Share

$0.00 (0.0%)

Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).

Revenue & Earnings

Balance Sheet

Share Statistics

Market Cap $7.92 Billion
Enterprise Value -
Dividend Yield $0.00 (0.0%)
1 Year Return +165.2%
52-Week High $121.16
52-Week Low $29.37
Beta 1.88
Outstanding Shares 94 Million
Avg 30 Day Volume 1.04 Million

Valuation

P/E Ratio 0.0
PEG -
Earnings per Share $0.00
Price to Sales Ratio -
Price to Book Ratio -
Revenue to Enterprise Value -
EBIT to Enterprise Value -
Total Debt to Enterprise Value -
Debt to Equity -

Profitability

Revenue -
Gross Profit -
EBIT -
Net Income -
Profit Margin -
Quarterly Earnings Growth (YoY) -
Return on Equity -
Return on Assets -
Return on Invested Capital -

News

Vista Partners LLC | San Diego-Based Fate Therapeutics To Host Q4/Full Year 2020 Earnings & Corporate Update Conference Call Wednesday, February 24, 2021

Vista Partners LLC | San Diego-Based Fate Therapeutics To Host Q4/Full Year 2020 Earnings & Corporate Update Conference Call Wednesday, February 24, 2021

San Diego-based Fate Therapeutics, Inc. (NASDAQ: FATE) has established a leadership position in the clinical development and manufacture of universal, off-the-shelf cell products using its propriet...

Vista Partners Vista Partners , 4 months ago
Critical Analysis: Fate Therapeutics (NASDAQ:FATE) versus QIAGEN (NYSE:QGEN)

Critical Analysis: Fate Therapeutics (NASDAQ:FATE) versus QIAGEN (NYSE:QGEN)

QIAGEN (NYSE:QGEN) and Fate Therapeutics (NASDAQ:FATE) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earn...

Modern Readers Modern Readers, 4 months ago
Fate Therapeutics (FATE) looks headed for a turnaround post-COVID

Fate Therapeutics (FATE) looks headed for a turnaround post-COVID

Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharma company, has been drawing the market’s attention after reporting positive results from advanced-stage clinical trials on its leuke...

AlphaStreet AlphaStreet, 5 months ago